多组学技术及其在肝细胞癌中的临床应用：当前进展与未来机遇

doi:10.24920/003984

Highlight

This review is structured in five parts including multi-omics in the clinical workflow of HCC, design and implementation of clinical cohort for HCC omics Study, methodology of radiomics, genomics and proteomics in HCC, and final summary of current limitation and future opportunities of multi-omics in HCC studies.

Abstract

Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the fourth leading cause of cancer related death worldwide. China covers over half of cases, leading HCC to be a vital threaten to public health. Despite advances in diagnosis and treatments, high recurrence rate remains a major obstacle in HCC management. Multi-omics currently facilitates surveillance, precise diagnosis, and personalized treatment decision making in clinical setting. Non-invasive radiomics utilizes preoperative radiological imaging to reflect subtle pixel-level pattern changes that correlate to specific clinical outcomes. Radiomics has been widely used in histopathological diagnosis prediction, treatment response evaluation, and prognosis prediction. High-throughput sequencing and gene expression profiling enabled genomics and proteomics to identify distinct transcriptomic subclasses and recurrent genetic alterations in HCC, which would reveal the complex multistep process of the pathophysiology. The accumulation of big medical data and the development of artificial intelligence techniques are providing new insights for our better understanding of the mechanism of HCC via multi-omics, and show potential to convert surgical/intervention treatment into an antitumorigenic one, which would greatly advance precision medicine in HCC management.

Key words: hepatocellular carcinoma, radiomics, proteomics, genomics, multi-omics

Wanshui Yang, Hanyu Jiang, Chao Liu, Jingwei Wei, Yu Zhou, Pengyun Gong, Bin Song, Jie Tian. Multi-Omics and Its Clinical Application in Hepatocellular Carcinoma: Current Progress and Future Opportunities[J].Chinese Medical Sciences Journal, 2021, 36(3): 173-186.

Figures/Tables 2

References 96.

1.	Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2016; 2:16018. doi: 10.1038/nrdp.2016.18. doi: 10.1038/nrdp.2016.18
2.	McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis 2015; 19(2):223-38. doi: 10.1016/j.cld.2015.01.001. doi: 10.1016/j.cld.2015.01.001
3.	International Agency for Research on Cancer. GLOBOCAN 2018. Estimated age-standardized incidence rates (World) in 2020, liver, both sexes, all ages. Available from https://gco.iarc.fr/today/online-analysis-map?v=2020&mode=population&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=11&type=0&statistic=5&prevalence=0&population_groupearth&color_palette=default&map_scale=quantile&map_nb_colors=5&continent=0&rotate=%255B10%252C0%255D (2020). Accessed August 16, 2021.
4.	Tabrizian P, Jibara G, Shrager B, et al. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 2015; 261(5):947-55. doi: 10.1097/SLA.0000000000000710. doi: 10.1097/SLA.0000000000000710
5.	Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018; 68(2):723-50. doi: 10.1002/hep.29913. doi: 10.1002/hep.29913
6.	Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 2017; 14(12):749-62. doi: 10.1038/nrclinonc.2017.141. doi: 10.1038/nrclinonc.2017.141
7.	Wei J, Jiang H, Gu D, et al. Radiomics in liver diseases: Current progress and future opportunities. Liver Int 2020; 40(9):2050-63. doi: 10.1111/liv.14555. doi: 10.1111/liv.14555
8.	Zhou Y, He L, Huang Y, et al. CT-based radiomics signature: a potential biomarker for preoperative prediction of early recurrence in hepatocellular carcinoma. Abdom Radiol (NY) 2017; 42(6):1695-704. doi: 10.1007/s00261-017-1072-0. doi: 10.1007/s00261-017-1072-0
9.	Cozzi L, Dinapoli N, Fogliata A, et al. Radiomics based analysis to predict local control and survival in hepatocellular carcinoma patients treated with volumetric modulated arc therapy. BMC Cancer 2017; 17(1):829. doi: 10.1186/s12885-017-3847-7. doi: 10.1186/s12885-017-3847-7
10.	Naganawa S, Enooku K, Tateishi R, et al. Imaging prediction of nonalcoholic steatohepatitis using computed tomography texture analysis. Eur Radiol 2018; 28(7):3050-8. doi: 10.1007/s00330-017-5270-5. doi: 10.1007/s00330-017-5270-5
11.	Kew MC. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int 2003; 23(6):405-9. doi: 10.1111/j.1478-3231.2003.00869.x. doi: 10.1111/j.1478-3231.2003.00869.x
12.	Seehawer M, Heinzmann F, D’Artista L, et al. Necroptosis microenvironment directs lineage commitment in liver cancer. Nature 2018; 562(7725):69-75. doi: 10.1038/s41586-018-0519-y. Erratum in Nature 2018; 564(7735):E9. doi 10.1038/s41586-018-0723-9. doi: 10.1038/s41586-018-0723-9
13.	Yuan D, Huang S, Berger E, et al. Kupffer cell-derived Tnf triggers cholangiocellular tumorigenesis through JNK due to chronic mitochondrial dysfunction and ROS. Cancer Cell 2017; 31(6):771- 89. e6. doi: 10.1016/j.ccell.2017.05.006. doi: 10.1016/j.ccell.2017.05.006
14.	Sia D, Villanueva A, Friedman SL, et al. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology 2017; 152(4):745-61. doi: 10.1053/j.gastro.2016.11.048. doi: 10.1053/j.gastro.2016.11.048
15.	Li Z, Mao Y, Huang W, et al. Texture-based classification of different single liver lesion based on SPAIR T2W MRI images. BMC Med Imaging 2017; 17(1):42. doi: 10.1186/s12880-017-0212-x. doi: 10.1186/s12880-017-0212-x
16.	Trivizakis E, Manikis GC, Nikiforaki K, et al. Extending 2-D convolutional neural networks to 3-D for advancing deep learning cancer classification with application to MRI liver uumor differentiation. IEEE J Biomed Health Inform 2019; 23(3):923-30. doi: 10.1109/JBHI.2018.2886276. doi: 10.1109/JBHI.2018.2886276
17.	Jiang H, Liu X, Chen J, et al. Man or machine? Prospective comparison of the version 2018 EASL, LI-RADS criteria and a radiomics model to diagnose hepatocellular carcinoma. Cancer Imaging 2019; 19(1):84. doi: 10.1186/s40644-019-0266-9. doi: 10.1186/s40644-019-0266-9
18.	Yao Z, Dong Y, Wu G, et al. Preoperative diagnosis and prediction of hepatocellular carcinoma: radiomics analysis based on multi-modal ultrasound images. BMC Cancer 2018; 18(1):1089. doi: 10.1186/s12885-018-5003-4. doi: 10.1186/s12885-018-5003-4
19.	Cucchetti A, Piscaglia F, Grigioni AD, et al. Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network: a pilot study. J Hepatol 2010; 52(6):880-8. doi: 10.1016/j.jhep.2009.12.037. doi: 10.1016/j.jhep.2009.12.037
20.	Zhou W, Zhang L, Wang K, et al. Malignancy characterization of hepatocellular carcinomas based on texture analysis of contrast-enhanced MR images. J Magn Reson Imaging 2017; 45(5):1476-84. doi: 10.1002/jmri.25454. doi: 10.1002/jmri.25454
21.	Wu M, Tan H, Gao F, et al. Predicting the grade of hepatocellular carcinoma based on non-contrast-enhanced MRI radiomics signature. Eur Radiol 2019; 29(6):2802-11. doi: 10.1007/s00330-018-5787-2. doi: 10.1007/s00330-018-5787-2
22.	Ye Z, Jiang H, Chen J, et al. Texture analysis on doi: 10.21147/j.issn.1000-9604.2019.05.10
	gadoxetic acid enhanced-MRI for predicting Ki-67 status in hepatocellular carcinoma: a prospective study. Chin J Cancer Res 2019; 31(5):806-17. doi: 10.21147/j.issn.1000-9604.2019.05.10. doi: 10.21147/j.issn.1000-9604.2019.05.10
23.	Wei J, Jiang H, Zeng M, et al. Prediction of microvascular invasion in hepatocellular carcinoma via deep learning: a multi-center and prospective validation study. Cancers (Basel) 2021; 13(10):2368. doi: 10.3390/cancers13102368. doi: 10.3390/cancers13102368
24.	Xu X, Zhang HL, Liu QP, et al. Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma. J Hepatol 2019; 70(6):1133-44. doi: 10.1016/j.jhep.2019.02.023. doi: 10.1016/j.jhep.2019.02.023
25.	Banerjee S, Wang DS, Kim HJ, et al. A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma. Hepatology 2015; 62(3):792-800. doi: 10.1002/hep.27877. doi: 10.1002/hep.27877
26.	Sun R, Limkin EJ, Vakalopoulou M, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol 2018; 19(9):1180-91. doi: 10.1016/S1470-2045(18)30413-3. doi: 10.1016/S1470-2045(18)30413-3
27.	Chen S, Feng S, Wei J, et al. Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging. Eur Radiol 2019; 29(8):4177-87. doi: 10.1007/s00330-018-5986-x. doi: 10.1007/s00330-018-5986-x
28.	Hectors SJ, Lewis S, Besa C, et al. MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma. Eur Radiol 2020; 30(7):3759-69. doi: 10.1007/s00330-020-06675-2. doi: 10.1007/s00330-020-06675-2
29.	Yuan C, Wang Z, Gu D, et al. Prediction early recurrence of hepatocellular carcinoma eligible for curative ablation using a radiomics nomogram. Cancer Imaging 2019; 19(1):21. doi: 10.1186/s40644-019-0207-7. doi: 10.1186/s40644-019-0207-7
30.	Ji GW, Zhu FP, Xu Q, et al. Radiomic features at contrast-enhanced CT predict recurrence in early stage hepatocellular carcinoma: a multi-institutional study. Radiology 2020; 294(3):568-79. doi: 10.1148/radiol.2020191470. doi: 10.1148/radiol.2020191470
31.	Hui TCH, Chuah TK, Low HM, et al. Predicting early recurrence of hepatocellular carcinoma with texture analysis of preoperative MRI: a radiomics study. Clin Radiol 2018; 73(12):1056. e11- 1056. e16. doi: 10.1016/j.crad.2018.07.109. doi: 10.1016/j.crad.2018.07.109
32.	Park HJ, Kim JH, Choi SY, et al. Prediction of therapeutic response of hepatocellular carcinoma to transcatheter arterial chemoembolization based on pretherapeutic dynamic CT and textural findings. AJR Am J Roentgenol 2017; 209(4):w211-w220. doi: 10.2214/AJR.16.17398. doi: 10.2214/AJR.16.17398
33.	Kim J, Choi SJ, Lee SH, et al. Predicting survival using pretreatment CT for patients with hepatocellular carcinoma treated with transarterial chemoembolization: comparison of models using radiomics. AJR Am J Roentgenol 2018; 211(5):1026-34. doi: 10.2214/AJR.18.19507. doi: 10.2214/AJR.18.19507
34.	Blanc-Durand P, van der Gucht A, Jreige M, et al. Signature of survival: a ¹⁸F-FDG PET based whole-liver radiomic analysis predicts survival after ⁹⁰Y-TARE for hepatocellular carcinoma. Oncotarget 2017; 9(4):4549-58. doi: 10.18632/oncotarget.23423. doi: 10.18632/oncotarget.23423
35.	Mulé S, Thiefin G, Costentin C, et al. Advanced hepatocellular carcinoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with sorafenib. Radiology 2018; 288(2):445-55. doi: 10.1148/radiol.2018171320. doi: 10.1148/radiol.2018171320
36.	Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2021; 7(1):6. doi: 10.1038/s41572-020-00240-3. doi: 10.1038/s41572-020-00240-3
37.	Calderaro J, Ziol M, Paradis V, et al. Molecular and histological correlations in liver cancer. J Hepatol 2019; 71(3):616-30. doi: 10.1016/j.jhep.2019.06.001. doi: 10.1016/j.jhep.2019.06.001
38.	Zucman-Rossi J, Villanueva A, Nault JC, et al. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 2015; 149(5):1226- 39.e4. doi: 10.1053/j.gastro.2015.05.061. doi: 10.1053/j.gastro.2015.05.061
39.	Totoki Y, Tatsuno K, Covington KR, et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet 2014; 46(12):1267-73. doi: 10.1038/ng.3126. doi: 10.1038/ng.3126
40.	Ahn SM, Jang SJ, Shim JH, et al. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology 2014; 60(6):1972-82. doi: 10.1002/hep.27198. doi: 10.1002/hep.27198
41.	Schulze K, Imbeaud S, Letouzé E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 2015; 47(5):505-11. doi: 10.1038/ng.3252. doi: 10.1038/ng.3252
42.	Guichard C, Amaddeo G, Imbeaud S, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012; 44(6):694-8. doi: 10.1038/ng.2256. doi: 10.1038/ng.2256
43.	Nault JC, Mallet M, Pilati C, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 2013; 4:2218. doi: 10.1038/ncomms3218. Erratum in Nat Commun 2013; 4:2577. doi 10.1038/ncomms3577. doi: 10.1038/ncomms3577
44.	Paterlini-Bréchot P, Saigo K, Murakami Y, et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 2003; 22(25):3911-6. doi: 10.1038/sj.onc.1206492. doi: 10.1038/sj.onc.1206492
45.	Bayard Q, Meunier L, Peneau C, et al. Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress. Nat Commun 2018; 9(1):5235. doi: 10.1038/s41467-018-07552-9. doi: 10.1038/s41467-018-07552-9
46.	Chiang DY, Villanueva A, Hoshida Y, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008; 68(16):6779-88. doi: 10.1158/0008-5472.CAN-08-0742. doi: 10.1158/0008-5472.CAN-08-0742
47.	Bressac B, Kew M, Wands J, et al. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350(6317):429-31. doi: 10.1038/350429a0. doi: 10.1038/350429a0
48.	Wang B, Huang G, Wang D, et al. Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol 2010; 53(3):508-18. doi: 10.1016/j.jhep.2010.03.026. doi: 10.1016/j.jhep.2010.03.026
49.	Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40(12):1461-5. doi: 10.1038/ng.257. doi: 10.1038/ng.257
50.	Buch S, Stickel F, Trépo E, et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet 2015; 47(12):1443-8. doi: 10.1038/ng.3417. doi: 10.1038/ng.3417
51.	Rebouissou S, Nault JC. Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol 2020; 72(2):215-29. doi: 10.1016/j.jhep.2019.08.017. doi: 10.1016/j.jhep.2019.08.017
52.	Hoshida Y, Nijman SM, Kobayashi M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009; 69(18):7385-92. doi: 10.1158/0008-5472.CAN-09-1089. doi: 10.1158/0008-5472.CAN-09-1089
53.	Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 2017; 169(7):1327- 41. e23. doi: 10.1016/j.cell.2017.05.046. doi: 10.1016/j.cell.2017.05.046
54.	Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006; 12(4):410-6. doi: 10.1038/nm1377. doi: 10.1038/nm1377
55.	Boyault S, Rickman DS, de Reyniès A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007; 45(1):42-52. doi: 10.1002/hep.21467. doi: 10.1002/hep.21467
56.	Sia D, Jiao Y, Martinez-Quetglas I, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology 2017; 153(3):812-26. doi: 10.1053/j.gastro.2017.06.007. doi: 10.1053/j.gastro.2017.06.007
57.	Llovet JM, Montal R, Sia D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 2018; 15(10):599-616. doi: 10.1038/s41571-018-0073-4. doi: 10.1038/s41571-018-0073-4
58.	Erstad DJ, Fuchs BC, Tanabe KK. Molecular signatures in hepatocellular carcinoma: a step toward rationally designed cancer therapy. Cancer 2018; 124(15):3084-104. doi: 10.1002/cncr.31257. doi: 10.1002/cncr.31257
59.	Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004; 40(3):667-76. doi: 10.1002/hep.20375. doi: 10.1002/hep.20375
60.	Calderaro J, Couchy G, Imbeaud S, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol 2017; 67(4):727-38. doi: 10.1016/j.jhep.2017.05.014. doi: 10.1016/j.jhep.2017.05.014
61.	Lachenmayer A, Alsinet C, Savic R, et al. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res 2012; 18(18):4997-5007. doi: 10.1158/1078-0432.CCR-11-2322. doi: 10.1158/1078-0432.CCR-11-2322
62.	Ruiz de Galarreta M, Bresnahan E, Molina-Sánchez P, et al. β-Catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov 2019; 9(8):1124-41. doi: 10.1158/2159-8290.CD-19-0074. doi: 10.1158/2159-8290.CD-19-0074
63.	Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131(2):461-9. doi: 10.1053/j.gastro.2006.05.021. doi: 10.1053/j.gastro.2006.05.021
64.	Lazcano G, Papuzinski C, Madrid E, et al. General concepts in biostatistics and clinical epidemiology: observational studies with cohort design. Medwave 2019; 19(11):e7748. Spanish and English. doi: 10.5867/medwave.2019.11.7748. doi: 10.5867/medwave.2019.11.7748
65.	Kim S, Shin J, Kim DY, et al. Radiomics on Gadoxetic acid-enhanced magnetic resonance imaging for prediction of postoperative early and late recurrence of single hepatocellular carcinoma. Clin Cancer Res 2019; 25(13):3847-55. doi: 10.1158/1078-0432.CCR-18-2861. doi: 10.1158/1078-0432.CCR-18-2861
66.	Grimes DA, Schulz KF. Cohort studies: marching towards outcomes. Lancet 2002; 359(9303):341-5. doi: 10.1016/S0140-6736(02)07500-1. doi: 10.1016/S0140-6736(02)07500-1
67.	Font C, Carmona-Bayonas A, Beato C, et al. Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study. Eur Respir J 2017; 49(1):1600282. doi: 10.1183/13993003.00282-2016. doi: 10.1183/13993003.00282-2016
68.	Liu L, Nevo D, Nishihara R, et al. Utility of inverse probability weighting in molecular pathological epidemiology. Eur J Epidemiol 2018; 33(4):381-92. doi: 10.1007/s10654-017-0346-8. doi: 10.1007/s10654-017-0346-8
69.	Dettori JR. Loss to follow-up. Evid Based Spine Care J 2011; 2(1):7-10. doi: 10.1055/s-0030-1267080. doi: 10.1055/s-0030-1267080
70.	Ferreira JC, Patino CM. Loss to follow-up and missing data: important issues that can affect your study results. J Bras Pneumol 2019; 45(2):e20190091. doi: 10.1590/1806-3713/e20190091. doi: 10.1590/1806-3713/e20190091
71.	Ogino S, Chan AT, Fuchs CS, et al. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011; 60(3):397-411. doi: 10.1136/gut.2010.217182. doi: 10.1136/gut.2010.217182
72.	López de Maturana E, Alonso L, Alarcón P, et al. Challenges in the integration of omics and non-omics data. Genes (Basel) 2019; 10(3):238. doi: 10.3390/genes10030238. doi: 10.3390/genes10030238
73.	López de Maturana E, Pineda S, Brand A, et al. Toward the integration of Omics data in epidemiological studies: still a “long and winding road”. Genet Epidemiol 2016; 40(7):558-69. doi: 10.1002/gepi.21992. doi: 10.1002/gepi.21992
74.	Lehmann TM, Gönner C, Spitzer K. Survey: interpolation methods in medical image processing. IEEE Trans Med Imaging 1999; 18(11):1049-75. doi: 10.1109/42.816070. doi: 10.1109/42.816070
75.	Lehmann T, Oberschelp W, Pelikan E, et al. Bildverarbeitung für die Medizin: Grundlagen, Modelle, Methoden, Anwendungen. Berlin, Heidelberg: Springer-Verlag; 2013. German. doi: 10.1007/978-3-642-60487-4. doi: 10.1007/978-3-642-60487-4
76.	Yang Q, Wei J, Hao X, et al. Improving B-mode ultrasound diagnostic performance for focal liver lesions using deep learning: a multicentre study. EBioMedicine 2020; 56:102777. doi: 10.1016/j.ebiom.2020.102777. doi: 10.1016/j.ebiom.2020.102777
77.	Zhao M, Zhang Z, Chow TWS. Trace ratio criterion based generalized discriminative learning for semi-supervised dimensionality reduction. Pattern Recognit 2012; 45(4):1482-99. doi: 10.1016/j.patcog.2011.10.008. doi: 10.1016/j.patcog.2011.10.008
78.	Zhao Z, Liu H. Spectral feature selection for supervised and unsupervised learning. ICML 2007: Proceedings of the 24th international conference on machine learning. June 20-24, 2007; Corvalis Oregon, USA. Vol. 227. p. 1151-1157. doi: 10.1145/1273496.1273641. doi: 10.1145/1273496.1273641
79.	Nie F, Huang H, Cai X, et al. Efficient and robust feature selection via Joint _2, 1-Norms Minimization. In: NIPS 2010: Proceedings of the 23rd International Conference on Neural Information Processing Systems. December 6-11, 2010; Vancouver, Cananda. Vol 2.p. 1813-1821.
80.	Cai D, Zhang C, He X. Unsupervised Feature Selection for Multi-Cluster Data. Proceedings of the 16th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. KDD 2010. July 25-28, 2010; Washington DC, USA. 2010. p. 333-342. doi: 10.1145/1835804.1835848. doi: 10.1145/1835804.1835848
81.	Zhang P, Feng J, Wu X, et al. Bioinformatics analysis of candidate genes and pathways related to hepatocellular carcinoma in China: a study based on public databases. Pathol Oncol Res 2021; 27:588532. doi: 10.3389/pore.2021.588532. doi: 10.3389/pore.2021.588532
82.	Zhou X, Shi M, Cao J, et al. S100 calcium binding protein A10, a novel oncogene, promotes the proliferation, invasion, and migration of hepatocellular carcinoma. Front Genet 2021; 12:695036. doi: 10.3389/fgene.2021.695036. doi: 10.3389/fgene.2021.695036
83.	Chen DB, Xie XW, Zhao YJ, et al. RFX5 promotes the progression of hepatocellular carcinoma through transcriptional activation of KDM4A. Sci Rep 2020; 10(1):14538. doi: 10.1038/s41598-020-71403-1. doi: 10.1038/s41598-020-71403-1
84.	Huo J, Wu L, Zang Y. Construction and validation of a reliable six-gene prognostic signature based on the TP53 alteration for hepatocellular carcinoma. Front Oncol 2021; 11:618976. doi: 10.3389/fonc.2021.618976. doi: 10.3389/fonc.2021.618976
85.	Sun Y, Wu L, Zhong Y, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell 2021; 184(2):404- 21. e16. doi: 10.1016/j.cell.2020.11.041. doi: 10.1016/j.cell.2020.11.041
86.	Li N, Long Y, Fan X, et al. Proteomic analysis of differentially expressed proteins in hepatitis B virus-related hepatocellular carcinoma tissues. J Exp Clin Cancer Res 2009; 28(1):122. doi: 10.1186/1756-9966-28-122. doi: 10.1186/1756-9966-28-122
87.	Wei D, Zeng Y, Xing X, et al. Proteome differences between hepatitis B Virus genotype-B- and genotype-C-induced hepatocellular carcinoma revealed by iTRAQ-based quantitative proteomics. J Proteome Res 2016; 15(2):487-98. doi: 10.1021/acs.jproteome.5b00838. doi: 10.1021/acs.jproteome.5b00838
88.	Du Z, Liu X, Wei X, et al. Quantitative proteomics identifies a plasma multi-protein model for detection of hepatocellular carcinoma. Sci Rep 2020; 10(1):15552. doi: 10.1038/s41598-020-72510-9. doi: 10.1038/s41598-020-72510-9
89.	Gao Q, Zhu H, Dong L, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. Cell 2019; 179(2): 561- 77. e22. doi: 10.1016/j.cell.2019.08.052. Erratum in: Cell 2019; 179(5):1240. doi 10.1016/j.cell.2019.10.038. doi: 10.1016/j.cell.2019.10.038
90.	Zhang F, Wang Y, Chen G, et al. Growing human hepatocellular tumors undergo a global metabolic reprogramming. Cancers (Basel) 2021; 13(8):1980. doi: 10.3390/cancers13081980. doi: 10.3390/cancers13081980
91.	Lu S, Cai S, Peng X, et al. Integrative transcriptomic, proteomic and functional analysis reveals ATP1B3 as a diagnostic and potential therapeutic target in hepatocellular carcinoma. Front Immunol 2021; 12:636614. doi: 10.3389/fimmu.2021.636614. doi: 10.3389/fimmu.2021.636614
92.	Wang L, Zhang Z, Li Y, et al. Integrated bioinformatic analysis of RNA binding proteins in hepatocellular carcinoma. Aging (Albany NY) 2020; 13(2):2480-505. doi: 10.18632/aging.202281. doi: 10.18632/aging.202281
93.	Segal E, Sirlin CB, Ooi C, et al. Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 2007; 25(6):675-80. doi: 10.1038/nbt1306. doi: 10.1038/nbt1306
94.	McCague C, Beer L. Radioproteomics in patients with ovarian cancer. Br J Radiol 2021; 94(1125):20201331. doi: 10.1259/bjr.20201331. doi: 10.1259/bjr.20201331
95.	Badic B, Tixier F, Cheze Le Rest C, et al. Radiogenomics in colorectal cancer. Cancers (Basel) 2021; 13(5):973. doi: 10.3390/cancers13050973. doi: 10.3390/cancers13050973
96.	Lo Gullo R, Daimiel I, Morris EA, et al. Combining molecular and imaging metrics in cancer: radiogenomics. Insights Imaging 2020; 11(1):1. doi: 10.1186/s13244-019-0795-6. doi: 10.1186/s13244-019-0795-6

[1]	Jin Lu,Shaoguang An,Junjie Ma,Yue Yang,Lei Zhang,Peng Yu,Heng Tao,Yunfan Chen,Haoxuan Zhang. Topoisomerase Ⅱα Gene as a Marker for Prognostic Prediction of Hepatocellular Carcinoma: A Bioinformatics Analysis [J]. Chinese Medical Sciences Journal, 2022, 37(4): 331-339.
[2]	Chen Xu, Huo Xiaofei, Wu Zhe, Lu Jingjing. Advances of Artificial Intelligence Application in Medical Imaging of Ovarian Cancers [J]. Chinese Medical Sciences Journal, 2021, 36(3): 196-203.
[3]	Jiazheng Li, Lei Tang. Radiomics in Antineoplastic Agents Development: Application and Challenge in Response Evaluation [J]. Chinese Medical Sciences Journal, 2021, 36(3): 187-195.
[4]	Qiong Chen,Xuefeng Yang. Research Progress in Targeted Therapy of Hepatocellular Carcinoma [J]. Chinese Medical Sciences Journal, 2021, 36(1): 57-65.
[5]	Xu Yanhong,Yang Jia,Meng Jie,Wang Han. Targeted MR Imaging Adopting T1-Weighted Ultra-Small Iron Oxide Nanoparticles for Early Hepatocellular Carcinoma: An in vitro and in vivo Study [J]. Chinese Medical Sciences Journal, 2020, 35(2): 142-150.
[6]	Wu Jianqiang, Qin Weiwei, Pan Li, Wang Xiaorong, Zhang Biao, Shan Guangliang, Gao Youhe. Regional Differences of the Urinary Proteomes in Healthy Chinese Individuals [J]. Chinese Medical Sciences Journal, 2019, 34(3): 157-167.
[7]	Dong Dexin, Ji Zhigang, Li Hanzhong, Yan Weigang, Zhang Yushi. Preliminary Application of WCX Magnetic Bead-Based Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry in Analyzing the Urine of Renal Clear Cell Carcinoma [J]. Chinese Medical Sciences Journal, 2017, 32(4): 248-252.
[8]	Zhang Xiufen, Yu Bo, Zhang Fuzheng, Guo Zijian, Li Lihua. microRNA-18a Promotes Cell Migration and Invasion Through Inhibiting Dicer l Expression in Hepatocellular Carcinoma In Vitro^△ [J]. Chinese Medical Sciences Journal, 2017, 32(1): 34-43.
[9]	Jian-bo Xu, Gang Xu, Guo-feng Chen, Dian-hua Gu, Jian-huai Zhang, Fu-zhen Qi*. Hepatocellular Carcinoma with Hypersplenic Thrombocytopenia and Situs Inversus Totalis: A Case Report [J]. Chinese Medical Sciences Journal, 2016, 31(2): 134-136.
[10]	Ye Jin, Li Zhou, Ke-min Jin, and Bao-cai Xing. Expression of Plasminogen Activator Inhibitor-2 is Negatively Associated with Invasive Potential in Hepatocellular Carcinoma Cells△ [J]. Chinese Medical Sciences Journal, 2013, 28(1): 16-19.
[11]	Yao Zhang, Hua Zhang, Au Elizabeth, Xiao-qing Liu. Epidemiology of Hepatitis B and Associated Liver Diseases in China [J]. Chinese Medical Sciences Journal, 2012, 27(4): 243-248.
[12]	Ting-ting He, and Jia-he Tian*. Application of Positron Emission Tomography Molecular Probes in Hepatocellular Carcinoma Biological Imaging [J]. Chinese Medical Sciences Journal, 2011, 26(2): 113-118.

Early edition

Current issue

Archive

Specialties & Topics

Author center

Reviewer center

Multi-Omics and Its Clinical Application in Hepatocellular Carcinoma: Current Progress and Future Opportunities

RichHTML

PDF (PC)

Supplement

Knowledge

Highlight

Abstract

Cite this article

share this article

Figures/Tables 2

References 96.

Related Articles 12

Metrics

Recommended 10